Cantor Fitzgerald analyst Yanni Souroutzidis reiterated an Overweight rating on Design Therapeutics Inc (NASDAQ: DSGN).The analyst commented, "USS is the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE